Bone Safety of Dolutegravir-Containing Regimens in People Living with HIV: Results from a Real-World Cohort

References

• Compston J. HIV infection and osteoporosis. Bonekey Rep. 2015;4:636. doi:10.1038/bonekey.2015.325709813
   PubMedGoogle Scholar
• Shiau S, Broun EC, Arpadi SM, Yin MT. Incident fractures in HIV-infected individuals: a systematic review and meta-analysis. AIDS. 2013;27(12):1949–1957. doi:10.1097/QAD.0b013e328361d24124126140
   PubMed Web of Science ®Google Scholar
• Premaor MO, Compston JE. The hidden burden of fractures in people living with HIV. JBMR Plus. 2018;2(5):247–256. doi:10.1002/jbm4.1005530283906
   PubMedGoogle Scholar
• Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: A meta-analytic review. AIDS. 2006;20(17):2165–2174. doi:10.1097/QAD.0b013e32801022eb17086056
   PubMed Web of Science ®Google Scholar
• Ofotokun I, Titanji K, Vunnava A, et al. Antiretroviral therapy induces a rapid increase in bone resorption that is positively associated with the magnitude of immune reconstitution in HIV infection. AIDS. 2016;30(3):405–414. doi:10.1097/QAD.000000000000091826760232
   PubMed Web of Science ®Google Scholar
• Kung YY, Felge U, Sarosi I, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature. 1999;402(6759):304–309. doi:10.1038/4630310580503
   PubMed Web of Science ®Google Scholar
• Compston J. HIV infection and bone disease. J Intern Med. 2016;280(4):350–358. doi:10.1111/joim.1252027272530
   PubMed Web of Science ®Google Scholar
• Hidron AI, Hill B, Guest JL, Rimland D. Risk factors for vitamin D deficiency among veterans with and without HIV infection. PLoS One. 2015;10(4):e0124168. doi:10.1371/journal.pone.012416825898185
   PubMed Web of Science ®Google Scholar
• Dao CN, Patel P, Overton ET, et al. Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitamin D levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the us general population. Clin Infect Dis. 2011;52(3):396–405. doi:10.1093/cid/ciq15821217186
   PubMed Web of Science ®Google Scholar
• Yin M, Stein E. The effect of antiretrovirals on vitamin D. Clin Infect Dis. 2011;52(3):406–408. doi:10.1093/cid/ciq16921217187
   PubMed Web of Science ®Google Scholar
• Madeddu G, Spanu A, Solinas P, et al. Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy. Q J Nucl Med Mol Imaging. 2004;48(1):39–48.15195003
   PubMed Web of Science ®Google Scholar
• Pinzone MR, Di Rosa M, Celesia BM, et al. LPS and HIV gp120 modulate monocyte/macrophage CYP27B1 and CYP24A1 expression leading to vitamin D consumption and hypovitaminosis D in HIV-infected individuals. Eur Rev Med Pharmacol Sci. 2013;17(14):1938–1950.23877860
   PubMed Web of Science ®Google Scholar
• Madeddu G, Spanu A, Solinas P, et al. Different impact of NNRTI and PI-including HAART on bone mineral density loss in HIV-infected patients. Eur Rev Med Pharmacol Sci. 2015;19(23):4576–4589.26698255
   PubMed Web of Science ®Google Scholar
• Rgen Stellbrink H-J, Orkin C, Arribas JR, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis. 2010;51(8):963–972. doi:10.1086/65641720828304
   PubMed Web of Science ®Google Scholar
• Hileman CO, Overton ET, McComsey GA. Vitamin D and bone loss in HIV. Curr Opin HIV AIDS. 2016;11(3):277–284. doi:10.1097/COH.000000000000027226890209
   PubMed Web of Science ®Google Scholar
• Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, Phase 3, non-inferiority trials. Lancet. 2015;385(9987):2606–2615. doi:10.1016/S0140-6736(15)60616-X25890673
   PubMed Web of Science ®Google Scholar
• Mills A, Arribas JR, Andrade-Villanueva J, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis. 2016;16(1):43–52. doi:10.1016/S1473-3099(15)00348-526538525
   PubMed Web of Science ®Google Scholar
• Post FA, Tebas P, Clarke A, et al. Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected adults with renal impairment: 96-week results from a single-arm, multicenter, open-label phase 3 study. J Acquir Immune Defic Syndr. 2017;71(5):530–537. doi:10.1097/QAI.0000000000001186
   Web of Science ®Google Scholar
• Bedimo RJ, Drechsler H, Jain M, et al. The RADAR study: week 48 safety and efficacy of RAltegravir combined with boosted DARunavir compared to tenofovir/emtricitabine combined with boosted darunavir in antiretroviral-naive patients. Impact on bone health. PLoS One. 2014;9(8):e106221. doi:10.1371/journal.pone.010622125170938
   PubMed Web of Science ®Google Scholar
• Brown TT, Moser C, Currier JS, et al. Changes in bone mineral density after initiation of antiretroviral treatment with Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/ Ritonavir,Darunavir/ Ritonavir,or Raltegravir. J Infect Dis. 2015;212(8):1241–1249. doi:10.1093/infdis/jiv19425948863
   PubMed Web of Science ®Google Scholar
• Borghetti A, Baldin G, Capetti A, et al. Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients. AIDS. 2017;31(3):457–459. doi:10.1097/QAD.000000000000135728079545
   PubMed Web of Science ®Google Scholar
• Rossetti B, Baldin G, Sterrantino G, et al. Efficacy and safety of dolutegravir-based regimens in advanced HIV-infected naïve patients: results from a multicenter cohort study. Antiviral Res. 2019;169. doi:10.1016/j.antiviral.2019.104552
   Web of Science ®Google Scholar
• Bagella P, Squillace N, Ricci E, et al. Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: data from the SCOLTA project. Infect Drug Resist. 2019;12:1385–1391. doi:10.2147/IDR.S20381331213857
   PubMed Web of Science ®Google Scholar
• Trottier B, Lake JE, Logue K, et al. Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study. Antivir Ther. 2017;22(4):295–305. doi:10.3851/IMP316628401876
   PubMed Web of Science ®Google Scholar
• Gatell JM, Assoumou L, Moyle G, et al. Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk. AIDS. 2017;31(18):2503–2514. doi:10.1097/QAD.000000000000167529112070
   PubMed Web of Science ®Google Scholar
• Tebas P, Kumar P, Hicks C, et al. Greater change in bone turnover markers for efavirenz/emtricitabine/tenofovir disoproxil fumarate versus dolutegravir R abacavir/lamivudine in antiretroviral therapy-naive adults over 144 weeks. AIDS. 2015;29(18):2459–2464. doi:10.1097/QAD.000000000000086326355674
   PubMed Web of Science ®Google Scholar
• McComsey GA, Lupo S, Parks D, et al. Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health. AIDS. 2018;32(4):477–485. doi:10.1097/QAD.000000000000172529239893
   PubMed Web of Science ®Google Scholar
• Ciccullo A, Avino AD, Lassandro AP, et al. Changes in bone mineral density in HIV-positive, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy: preliminary results from clinical practice. Infez Med. 2018;26(4):336–340.30555137
   PubMedGoogle Scholar
• DAIDS. Division of aids table for grading the severity of adult and pediatric adverse events division of aids table for grading the severity of adult and pediatric adverse events. National Institute of Allergy and Infectious Diseases; 2017 Available from: https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf. Accessed 73, 2020.
   Google Scholar
• Madeddu G, De Socio GVL, Ricci E, et al. Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: results from the SCOLTA project long-term surveillance. Int J Antimicrob Agents. 2015;45(3):289–294. doi:10.1016/j.ijantimicag.2014.10.01325476452
   PubMed Web of Science ®Google Scholar
• Bonfanti P, Martinelli C, Ricci E, et al. An Italian approach to postmarketing monitoring: preliminary results from the SCOLTA (Surveillance Cohort Long-term Toxicity Antiretrovirals) project on the safety of lopinavir/ritonavir. J Acquir Immune Defic Syndr. 2005;39(3):317–320. doi:10.1097/01.qai.0000164248.56722.3c15980692
   PubMed Web of Science ®Google Scholar
• DHHS Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents Living with HIV developed. Department of Health and Human Services. doi:10.1108/14630010710742455
   Google Scholar
• Wilson KE Practical consideration when replacing a DXA system. Available from: https://hologiced.com/wp-content/uploads/2018/06/Wilson-KE.-Practical-Considerations-When-Replacing-a-DXA-System.pdf. Accessed 73, 2020.
   Google Scholar
• Pedrazzoni M, Girasole G, Bertoldo F, et al. Definition of a population-specific DXA reference standard in Italian women: the Densitometric Italian Normative Study (DINS). Osteoporos Int. 2003;14(12):978–982. doi:10.1007/s00198-003-1521-114530829
   PubMed Web of Science ®Google Scholar
• Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ - Tech Rep Ser. 1994;4(6):368–381.
   Google Scholar
• De Socio GV, Maggi P, Ricci E, et al. Smoking habits in human immunodeficiency virus-infected people from Italy: a cross-sectional analysis of the STOPSHIV cohort. AIDS Res Hum Retroviruses. 2019;36(1):19–26. doi:10.1089/aid.2019.011531502468
   PubMed Web of Science ®Google Scholar
• Bernardino JI, Mocroft A, Mallon PW, et al. Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial. Lancet HIV. 2015;2(11):464–473. doi:10.1016/S2352-3018(15)00181-2
   Web of Science ®Google Scholar
• Bloch M, Tong W, Hoy J, et al. Switch from tenofovir to raltegravir increases low bone mineral density and decreases markers of bone turnover over 48 weeks. HIV Med. 2014;15(6):373–380. doi:10.1111/hiv.1212324460797
   PubMed Web of Science ®Google Scholar
• Nia Negredo E, Domingo P, Pérez-Álvarez N, et al. Improvement in bone mineral density after switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: two-centre randomized pilot study (OsteoTDF study). J Antimicrob Chemother. 2014;69:3368–3371. doi:10.1093/jac/dku30025125679
   PubMed Web of Science ®Google Scholar
• Arribas JR, Thompson M, Sax PE, et al. Brief report: randomized, double-blind comparison of tenofovir alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated with Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 treatment: week 144 results. J Acquir Immune Defic Syndr. 2017;75(2):211–218. doi:10.1097/QAI.000000000000135028282300
   PubMed Web of Science ®Google Scholar
• DeJesus E, Haas B, Segal-Mauer S, et al. Superior efficacy and improved renal and bone safety after switching from a tenofovir disoproxil fumarate (TDF)- to a Tenofovir Alafenamide (TAF)-based Regimen Through 96 Weeks of Treatment. AIDS Res Hum Retroviruses. 2018;34(4):337–342. doi:10.1089/aid.2017.020329368537
   PubMed Web of Science ®Google Scholar
• Gallant J, Lazzarin A, Mills A, et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 2017;390(10107):2063–2072. doi:10.1016/S0140-6736(17)32299-728867497
   PubMed Web of Science ®Google Scholar
• Molina JM, Ward D, Brar I, et al. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phas. Lancet HIV. 2018;5(7):e357–e365. doi:10.1016/S2352-3018(18)30092-429925489
   PubMed Web of Science ®Google Scholar
• Wijting IEA, Rokx C, Zillikens MC, et al. Changes in renal, bone, lipid, and inflammation markers in HIV-1 patients after combination antiretroviral therapy simplification to dolutegravir monotherapy. Int J STD AIDS. 2019;30(11):1042–1048. doi:10.1177/095646241984896231431155
   PubMed Web of Science ®Google Scholar
• Vescini F, Cozzi-Lepri A, Borderi M, et al. Prevalence of hypovitaminosis D and factors associated with vitamin D deficiency and morbidity among HIV-infected patients enrolled in a large Italian cohort. J Acquir Immune Defic Syndr. 2011;58(2):163–172. doi:10.1097/QAI.0b013e31822e57e921826011
   PubMed Web of Science ®Google Scholar
• Brown TT, Hoy J, Borderi M, et al. Recommendations for evaluation and management of bone disease in HIV. Clin Infect Dis. 2015;60(8):1242–1251. doi:10.1093/cid/civ01025609682
   PubMed Web of Science ®Google Scholar